Medpace (NASDAQ:MEDP) VP Sells $10,872,620.00 in Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) VP Susan Burwig sold 16,060 shares of Medpace stock in a transaction dated Monday, October 26th. The stock was sold at an average price of $677.00, for a total value of $10,872,620.00. Following the transaction, the vice president owned 57,624 shares of the company’s stock, valued at $39,011,448. The trade was a 21.80% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Medpace Stock Performance

NASDAQ MEDP opened at $652.01 on Friday. The firm’s fifty day moving average price is $619.12 and its two-hundred day moving average price is $531.32. Medpace Holdings, Inc. has a fifty-two week low of $373.00 and a fifty-two week high of $693.97. The stock has a market cap of $18.24 billion, a PE ratio of 37.56, a PEG ratio of 2.63 and a beta of 1.18.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Wednesday, October 21st. The company reported $4.84 earnings per share for the quarter, topping the consensus estimate of $4.44 by $0.40. Medpace had a return on equity of 99.76% and a net margin of 18.24%. The firm had revenue of $716.00 million during the quarter, compared to analyst estimates of $714.47 million. During the same period last year, the company posted $3.86 EPS. The business’s quarterly revenue was up 8.5% on a year-over-year basis. As a group, sell-side analysts predict that Medpace Holdings, Inc. will post 18.06 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently commented on the stock. Mizuho set a $730.00 price target on shares of Medpace in a research note on Friday, October 23rd. Truist Financial lifted their price objective on shares of Medpace from $609.00 to $633.00 and gave the stock a “hold” rating in a research note on Friday, October 23rd. UBS Group raised their price objective on Medpace from $673.00 to $700.00 and gave the stock a “neutral” rating in a report on Friday, October 23rd. Jefferies Financial Group reissued a “hold” rating on shares of Medpace in a research report on Monday, September 14th. Finally, BMO Capital Markets lifted their price target on Medpace from $600.00 to $670.00 and gave the stock a “market perform” rating in a research note on Monday. Three research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $649.27.

Institutional Investors Weigh In On Medpace

Institutional investors and hedge funds have recently bought and sold shares of the business. Novem Group lifted its stake in Medpace by 1.0% during the third quarter. Novem Group now owns 2,127 shares of the company’s stock valued at $1,328,000 after buying an additional 22 shares in the last quarter. Fifth Third Wealth Advisors LLC raised its stake in shares of Medpace by 3.2% in the 3rd quarter. Fifth Third Wealth Advisors LLC now owns 783 shares of the company’s stock valued at $489,000 after buying an additional 24 shares in the last quarter. Balefire LLC lifted its holdings in Medpace by 6.1% during the 1st quarter. Balefire LLC now owns 451 shares of the company’s stock valued at $217,000 after purchasing an additional 26 shares during the last quarter. Motley Fool Asset Management LLC grew its holdings in Medpace by 3.3% during the third quarter. Motley Fool Asset Management LLC now owns 819 shares of the company’s stock worth $511,000 after purchasing an additional 26 shares during the period. Finally, Root Financial Partners LLC raised its stake in Medpace by 34.1% in the 1st quarter. Root Financial Partners LLC now owns 122 shares of the company’s stock worth $59,000 after purchasing an additional 31 shares in the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

About Medpace

Medpace Holdings, Inc is a contract research organization (CRO) that provides clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports sponsors throughout the development process, from early-stage planning and regulatory submissions through clinical trial execution, data management, analysis and reporting.

Medpace’s services include Phase I through Phase IV clinical research, clinical monitoring, biostatistics, data management, medical writing, pharmacovigilance, regulatory consulting and central laboratory services.